Year: 2019
BerGenBio presents new preliminary clinical and biomarker data showing durable response & median survival rates in Phase II trial with bemcentinib and KEYTRUDA in patients with advanced NSCLC at ASCO 2019
June 2, 2019
Phase II trial evaluating bemcentinib in combination with KEYTRUDA in advanced NSCLC patients shows 12-month…
Read More
BERGENBIO ASA: INVITATION TO ASCO UPDATE CALL
May 31, 2019
Bergen, Norway, 31 May 2019 – BerGenBio ASA (OSE:BGBIO), will share its latest updates and data…
Read More
BerGenBio to present new NSCLC and AML clinical data and biomarker data from Phase II development programme with selective AXL inhibitor bemcentinib at ASCO 2019
May 15, 2019
Two peer reviewed abstracts on Phase II clinical data with bemcentinib accepted for presentation at…
Read More
BerGenBio completes recruitment into second stage of Phase II trial with selective AXL inhibitor bemcentinib in combination with KEYTRUDA® in patients with advanced NSCLC
May 8, 2019
Phase II, Simon two-stage trial evaluating bemcentinib and KEYTRUDA in previously treated NSCLC post chemotherapy…
Read More
BERGENBIO ASA: RESULTS FOR THE FIRST QUARTER 2019
May 8, 2019
Advanced leukaemia (AML/MDS): Phase II trial fully recruited and combination trial with low-intensity chemotherapy meets…
Read More
BERGENBIO ASA: INVITATION TO FIRST QUARTER PRESENTATION AND WEBCAST
April 24, 2019
Bergen, Norway, 24 April 2019 – BerGenBio ASA (OSE:BGBIO), will announce its results for the…
Read More
